Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04622462 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 7, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 31, 2024 to Dec 31, 2025
    • Publications: 5 to 6
    v4
  2. Primary completion date: Dec 31, 2023 to Dec 31, 2024v3
  3. Primary completion date: Dec 31, 2021 to Dec 31, 2023v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.
Trial Details
NCT Number NCT04622462
Lead Sponsor Proteocyte Diagnostics Inc.
Conditions
(from sponsor)		 Oral Neoplasm
Related terms Disease, Erythroplasia, Hyperplasia, Keratoderma, Palmoplantar, Epidermolytic, Leukoplakia, Mouth Neoplasms, Squamous Cell Carcinoma of Head and Neck
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov